Effect of Monitoring Continuous Glucose Levels and Physical Activity Via Wearables on Cardiovascular Risk Factors
- Conditions
- Coronary Heart DiseasePhysical ActivityCardiovascular Risk Factors
- Interventions
- Device: Fitbit Inspire 2Device: Abbott Freestyle Libre 3
- Registration Number
- NCT05969665
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Brief Summary
The study aims to assess the effect of smart watches and continuous glucose measuring devices on cardiovascular risk factors.
- Detailed Description
Within a period of 4 months 100 patients will be recruited and randomised to the intervention or control arm (1:1) for a duration of 3 months. Randomisation will be stratified by age, sex, BMI, diabetes, blood pressure, and duration after finishing cardiac rehabilitation. Patients randomised to the intervention arm will be given a smart watch as well as a continuous blood glucose measurement device with detailed instructions. At baseline and at the end of the study questionnaires will be answered and anthropomorphic measurements attained. Blood samples will be drawn at baseline and after an intervention period of 3 months in all subjects. Additional data on sleep, temperature, heart rate (resting and exercise), breathing rate, activity and exercise, oxygen saturation and daily weight will be collected through the Fitbit web application programming interface (API).
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 100
- Informed Consent signed by the subject
- Completed outpatient cardiac rehabilitation
- Diagnosis of coronary heart disease
- Access to a smartphone for the duration of the study
- 18 years or older on the date of consent
- Diseases which limit physical activity including angina with incomplete revascularisation, arrhythmogenic cardiomyopathy, stroke with residual disease, and major orthopaedic disorders
- Known or suspected non-compliance
- Inability to follow the procedures of the investigation, e.g., due to language problems, psychological disorders, dementia, etc. of the subject
- Diabetic patients receiving insulin therapy
- Lack of proficiency with smart phone/watch
- Current participation in any other clinical trial, which may confound the results of this trial.
- NYHA (New York Heart Association) class III or IV congestive heart failure
- Pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Wearing a smartwatch and glucose measuring device Abbott Freestyle Libre 3 The intervention will be wearing a smart watch as well as continuous glucose monitoring with direct feedback via an application. Participants will wear these devices for 3 months. Wearing a smartwatch and glucose measuring device Fitbit Inspire 2 The intervention will be wearing a smart watch as well as continuous glucose monitoring with direct feedback via an application. Participants will wear these devices for 3 months.
- Primary Outcome Measures
Name Time Method Change in cardiovascular risk factor score HbA1c at baseline and after 3 month For the risk factor HbA1c 0 to 2 points will be awarded. 2 points will be rewarded if the patient reaches the goals according to ESC-Guidelines where applicable, 1 point if the patient reaches the goal partially and 0 if the patient does not reach the goal.
Goals according to ESC Guidelines:
DM (diabetes mellitus) HbA1c \< 7.0% or \< 6.5% in recent diagnosis No DM \< 5.7% (cut-off prediabetes)
Points according to goals:
2 = \< 5.7 %
1 = 5.7 - 6.5 % 0 = \> 6.5 %Change in cardiovascular risk factor score blood pressure at baseline and after 3 month For the risk factor blood pressure 0 to 2 points will be awarded. 2 points will be rewarded if the patient reaches the goals according to ESC (European Society of Cardiology) -Guidelines where applicable, 1 point if the patient reaches the goal partially and 0 if the patient does not reach the goal.
Goals according to ESC Guidelines:
Systolic 120-130 mmHg (18-69y.) Systolic \< 140 mmHg (70y.) Diastolic \< 80 mmHg (all ages)
Points according to goals:
2 = age related SBP (systolic blood pressure) \& DBP (diastolic blood pressure) goals
1 = \< 140 mmHg, \> 130 mmHg 18-69yr. or \< 140 mmHg and \> 90 mmHg DBP \>70yr 0 = SBP \> 140 mmHgChange in cardiovascular risk factor score LDL at baseline and after 3 month For the risk factor LDL 0 to 2 points will be awarded. 2 points will be rewarded if the patient reaches the goals according to ESC-Guidelines where applicable, 1 point if the patient reaches the goal partially and 0 if the patient does not reach the goal.
Goals according to ESC Guidelines:
LDL \<1.4 mmol/l and 50% reduction from baseline
Points according to goals:
2 = \< 1.4 mmol/l
1 = \< 1.8 mmol/l 0 = \> 1.8 mmol/lChange in cardiovascular risk factor score BMI at baseline and after 3 month For the risk factor BMI 0 to 2 points will be awarded. 2 points will be rewarded if the patient reaches the goals according to ESC-Guidelines where applicable, 1 point if the patient reaches the goal partially and 0 if the patient does not reach the goal.
Goals according to ESC Guidelines:
BMI 20-25 kg/m2 AC (Abdominal circumference) \< 102 (men) \< 88 (women) WHR (waist to hip ratio) 0.75-0.9 men \& 0.70-0.85 women
Points according to goals:
2 = BMI and AC in range
1 = only BMI or AC in range 0 = nothing in rangeChange in cardiovascular risk factor score smoking at baseline and after 3 month For the risk factor smoking 0 or 3 points will be awarded.
Points according to goals:
Smoking (yes/no) 3 = no 0 = yesChange in cardiovascular risk factor score physical activity at baseline and after 3 month For the risk factor physical activity 0 to 2 points will be awarded. 2 points will be rewarded if the patient reaches the goals according to ESC-Guidelines where applicable, 1 point if the patient reaches the goal partially and 0 if the patient does not reach the goal.
Goals according to ESC Guidelines:
\> 150min/week moderate PA (mPA), better 300min/week (self-reported) or \> 75min/week vigorous PA (vPA), better 150min/week (self-reported)
Points according to goals:
2 = \> 300 min. mPA or \> 150 min. vPA
1 = \> 150 min. mPA or \> 75 min. vPA 0 = \< 150 min. mPA or \< 75 min. vPA Or mix or mPA and vPA respectivelyChange in cardiovascular risk factor score nutrition at baseline and after 3 month For the risk factor nutrition 0 to 2 points will be awarded. 2 points will be rewarded if the patient reaches the goals according to ESC-Guidelines where applicable, 1 point if the patient reaches the goal partially and 0 if the patient does not reach the goal.
Goals according to ESC Guidelines:
≥ 5 portions fruit/vegetables a day Unsalted nuts ≥ 3x/week Reduction in saturated fats
Points according to goals:
2 = 5/day OR 4/day + nuts 3x/week + reduction in saturated fats
1 = 4/day OR 3/day + nuts 3x/week + reduction in saturated fats 0 = \< 4/day
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital Basel
🇨🇭Basel, Switzerland